Skip to main content
Premium Trial:

Request an Annual Quote

New York Conditionally Approves CombiMatrix's Miscarriage Test for Fresh, FFPE Tissues

NEW YORK (GenomeWeb) – CombiMatrix today said that the New York State Department of Health conditionally approved the CombiSNP Array for Pregnancy Loss for testing on fresh and formalin-fixed, paraffin-embedded patient samples.

It is the company's second conditional approval from the state this month for the SNP-based chromosomal microarray analysis test, following a similar decision on CombiSNP for pediatric development disorders. Also, in June 2013, New York conditionally approved the test for miscarriage analysis on fresh tissue.

"The availability of this SNP-based CMA test provides New York physicians the flexibility to either use fresh tissue or stored FFPE tissue when fresh tissue is not available," CombiMatrix CEO Mark McDonough said in a statement.

Under conditional approval, the firm can market the test in New York while the test is under Clinical Laboratory Reference System review. After the review is completed, the test will either be fully approved for marketing, or New York can ask for additional information before making a final decision.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.